The development of a novel protocol for the treatment of de novo childhood acute myeloid leukemia in a single institution in Taiwan

Ting Chi Yeh, Hsi Che Liu, Lin Yen Wang, Shu Huey Chen, Wei Ying Lin, Der Cherng Liang

Research output: Contribution to journalArticle

4 Citations (Scopus)


From November 1, 1995 to July 31, 2004, 49 children with de novo acute myeloid leukemia (AML) were treated at our institution. One patient who was treated by a different protocol was excluded. In total, 48 patients with de novo AML were enrolled in this study. Forty-two patients with AML other than acute promyelocytic leukemia (non-APL) were treated consecutively with 2 novel protocols: Mackay Memorial Hospital (MMH)-AML-96, designed as a pilot phase, and Taiwan Pediatric Oncology Group (TPOG)-AML-97A, on the basis of MMH-AML-96 with minor modifications. Six patients with APL were treated consecutively with 2 protocols, TPOG-APL-97 and APL-2001. As of July 31, 2006, the remission rates were 79%, 92%, and 98% after 1, 2, and 3 courses of induction therapy, respectively. The 5-year overall survival was 64%±6.9% (SE), and the 5-year event-free survival was 60%±7.1%; for non-APL AML, the rates were 62%±7.5% and 59%±7.6%; for APL, 83±15.2 and 67±19.3%. Among the factors analyzed, a complete remission achieved after 1 course of induction therapy, lactate dehydrogenase

Original languageEnglish
Pages (from-to)826-831
Number of pages6
JournalJournal of Pediatric Hematology/Oncology
Issue number12
Publication statusPublished - Dec 2007
Externally publishedYes



  • Acute myeloid leukemia
  • Acute promyelocytic leukemia
  • Outcome
  • Protocol design
  • Treatment

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this